Genome-wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma.
Taishi NakamuraKohei FukuokaYoshiko NakanoKai YamasakiYuko MatsushitaSatoshi YamashitaJunji IkedaNaoko UdakaReo TanoshimaNorio ShibaKensuke TateishiShoji YamanakaTetsuya YamamotoJunko HiratoKoichi IchimuraPublished in: Cancer science (2019)
In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma (PXA) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma (GBM) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genome-wide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA.